Sanofi Reports Results of Toujeo (insulin glargine 300 Units/mL) in P-III EDITION JUNIOR Study in Children and Adolescents with Type 1 Diabetes

 Sanofi Reports Results of Toujeo (insulin glargine 300 Units/mL) in P-III EDITION JUNIOR Study in Children and Adolescents with Type 1 Diabetes

Sanofi Reports Results of Toujeo (insulin glargine 300 Units/mL) in P-III EDITION JUNIOR Study in Children and Adolescents with Type 1 Diabetes

Shots:

  • The P-III EDITION JUNIOR study involves assessing Toujeo vs Gla-100 (insulin glargine 100 Units/mL) in 463 children and adolescents aged 6-17yrs. with T1D for at least 1yr. and with HbA1c b/w 7.5% and 11.0% at screening
  • The P-III EDITION JUNIOR study resulted in meeting its 1EPs i.e, reduction in average blood sugar over 6 months with both treatments and similar risk of hypoglycemia; the lower number of patients experienced severe hypoglycemia & hyperglycemia with ketosis
  • Toujeo is long-acting insulin for adults with diabetes, regulating blood sugar level and has received EMA’s CHMP positive opinion for expanded indication in children and adolescents aged 6-17yrs. with diabetes with the anticipated EC’s decision in the coming months

Click here to­ read full press release/ article | Ref: Sanofi | Image: The Diabetes Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post